



The Global Language of Business

Clinical Trial Request For Inventory Report Business Message Standard (BMS)

Release 3.7, Ratified, Mar 2025



Document Summary

Document Item	Current Value
Document Name	Clinical Trial Request For Inventory Report Business Message Standard (BMS)
Document Date	Mar 2025
Document Version	3.7
Document Issue	1
Document Status	Ratified

Work Request Reference

Date of WR Submission to GSMP:	WR Submitter(s):	Refer to Work Request (WR) Number(s):

Business Requirements Document (BRAD) Reference

BRAD Title	BRAD Issue Date	BRAD Version

Document Change History

Date of Change	Version	Changed By	Reason for Change	Summary of Change
3-Apr-2020	BMS 3.4.2	Mark Van Eeghem	Initial Draft	Initial Draft
10-Aug-2020	BMS 3.4.2	Piergiorgio Licciardello	Change after workgroup revision	Structure changes, classes and attributes definitions
24-Sep-2020	BMS 3.4.2	Piergiorgio Licciardello	Group revision	
14-Oct-2020	BMS 3.4.2	Piergiorgio Licciardello	Updates after community revision	
29-Oct-2020	BMS 3.4.2	Piergiorgio Licciardello	Errata corrige	Class diagram update
15-Jan-2021	BMS 3.5	Miklos Bolyky	BMS Release 3.5	See summary of changes
05-Jan-2022	BMS 3.5.1	Miklos Bolyky	BMS Release 3.5.1	See summary of changes
23-Jan-2022	BMS 3.6	Miklos Bolyky	BMS Release 3.6	See summary of changes
15-Mar-2025	BMS 3.7	Miklos Bolyky	BMS Release 3.7	See summary of changes



Disclaimer

GS1®, under its IP Policy, seeks to avoid uncertainty regarding intellectual property claims by requiring the participants in the Work Group that developed this **Clinical Trial Request For Inventory Report Business Message Standard (BMS)** to agree to grant to GS1 members a royalty-free licence or a RAND licence to Necessary Claims, as that term is defined in the GS1 IP Policy. Furthermore, attention is drawn to the possibility that an implementation of one or more features of this Specification may be the subject of a patent or other intellectual property right that does not involve a Necessary Claim. Any such patent or other intellectual property right is not subject to the licencing obligations of GS1. Moreover, the agreement to grant licences provided under the GS1 IP Policy does not include IP rights and any claims of third parties who were not participants in the Work Group.

Accordingly, GS1 recommends that any organization developing an implementation designed to be in conformance with this Specification should determine whether there are any patents that may encompass a specific implementation that the organisation is developing in compliance with the Specification and whether a licence under a patent or other intellectual property right is needed. Such a determination of a need for licencing should be made in view of the details of the specific system designed by the organisation in consultation with their own patent counsel.

THIS DOCUMENT IS PROVIDED "AS IS" WITH NO WARRANTIES WHATSOEVER, INCLUDING ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, FITNESS FOR PARTICULAR PURPOSE, OR ANY WARRANTY OTHERWISE ARISING OUT OF THIS SPECIFICATION. GS1 disclaims all liability for any damages arising from use or misuse of this Standard, whether special, indirect, consequential, or compensatory damages, and including liability for infringement of any intellectual property rights, relating to use of information in or reliance upon this document.

GS1 retains the right to make changes to this document at any time, without notice. GS1 makes no warranty for the use of this document and assumes no responsibility for any errors which may appear in the document, nor does it make a commitment to update the information contained herein.

GS1 and the GS1 logo are registered trademarks of GS1 AISBL.

Table of Contents

1	Business Domain View	5
1.1	Introduction	5
1.2	References	5
2	Business Context	6
3	Business Transaction View	6
4	Business Information View	8
4.1	Clinical Trial Request For Inventory Report	8
4.2	Enumerations (message specific)	11
4.3	Code Lists	11
5	Business Message Examples	11
5.1	Example 1	11
6	Implementation Considerations.....	12
6.1	User Guide	12
6.2	Message Specific Considerations	12
7	Summary of Changes	12
7.1	BMS Release 3.4.2	12
7.2	BMS Release 3.5	13
7.3	BMS Release 3.5.1	13
7.4	BMS Release 3.6	13
7.5	BMS Release 3.7	13
8	Appendices	13
9	Acknowledgements.....	13
9.1.1	Work Group	13
9.1.2	Development Team Members	15

1 Business Domain View

1.1 Introduction

Purpose

The Request for Inventory Report communicates a request for provision of an inventory report, which gives current information about inventory levels. The inventory report request is related to finished products as identified GTINs.

This Request for Inventory Business Message Standard is one part of a suite of documents designed to provide the detailed technical mappings to GS1 message formats for EDI messages being implemented for Clinical Trials.

The other documents in this suite are:

- Inventory Release
- Shipment Request
- Shipment Notification
- Shipment Confirmation
- Despatch Advice
- Receiving Advice
- Inventory Report
- Kit Status Change
- Dispensing Advice

Scope

The scope of this work includes all messages identified in [the GS1 Pharmaceutical Clinical Trial Electronic Messaging Standard Implementation Guideline](#), hereafter called 'the Guideline', section 4.2.

Considerations

The workgroup that developed this mapping document has ensured that the messages and associated mappings are technology and sponsor agnostic.

It is important that organisations implementing electronic business messaging in line with this guideline undertake an appropriate assessment to ensure that the blinding status of the trial is respected in the messages exchanged.

Messaging communications with transport providers / couriers / carriers are out of scope because there are already electronic processes in place and altering them would not add value.

1.2 References

Reference Name	Description
GS1 Pharmaceutical Clinical Trial Electronic Messaging Standard Implementation Guideline ,	The guideline details the business requirement of the clinical trials context, both in terms of process design and data set shared between the actors

2 Business Context

Context Category	Value(s)
Industry	Healthcare, Pharmaceuticals & Medical Devices
Geopolitical	All
Product	All
Process	Clinical Trials
System Capabilities	GS1 System
Official Constraints	None

3 Business Transaction View

Business Process Participants

As detailed in *the Guideline*, section 4.1, the diagram and table below provide an overview of the main actors involved in the process.




Table 3-1 Roles and responsibilities

Role	Responsibility in process
Manufacturer/sponsor	Has overall responsibility for the trial, and produces the Investigational Product (IP)
Contract Manufacturing Organisation (CMO)	Manufactures and may package IP and IP kits at the direction of the manufacturer / sponsor
Packaging site	Packages and labels the IP and IP kits
Distributor (with warehouse)	Warehouses and distributes the IP kits as needed to the sites
Carrier (transporting the goods)	Logistics provider moving the IP kits at the request of other stakeholders
Clinical trial site	The healthcare provider location where the trial is conducted and dispensing to the patient typically occurs
Return facility	Responsible for receipt of any IP kits returned from trial sites
Distribution Management Entity (DME)	A term used to identify the system(s) managing, distribution, and disposition of clinical supplies. In many cases this is the

	interactive technology IRT system, portal, a set of tools or different databases used to share information during a clinical trial, etc.
--	--

Use Case Diagram

N/A

Use Case Description

Below is the use case detailed in *the Guideline*, section 7.8.

Performance goals	A request to drive the subsequent action of sending an inventory report.						
Preconditions	Unique identification of locations, trade items and logistics units will be undertaken. Correct identification receiver (Ship To/inventory location) are in place.						
Postconditions	None identified						
Scenario	<p>Begins when the sponsor sends a message to ask for inventory levels from across the supply chain.</p> <p>Continues with...</p> <table><tr><th>Step #</th><th>Actor</th><th>Activity step</th></tr><tr><td>1</td><td>Receiver</td><td>Receives communication.</td></tr></table> <p>Ends when the Receiver takes action to provide inventory level information.</p>	Step #	Actor	Activity step	1	Receiver	Receives communication.
Step #	Actor	Activity step					
1	Receiver	Receives communication.					
Alternative scenario	Not applicable						
Related requirements	None identified						
Related rules	None identified						

Activity Diagram(s)

Not applicable


Sequence Diagram(s)

Not applicable

4 Business Information View

4.1 Clinical Trial Request For Inventory Report

Class diagram





The content of the ClinicalTrialRequestForInventoryReport class, its structure and component definitions can be accessed in the GS1 Navigator: [Navigator link](#)

Content	Attribute / Role	Datatype / Secondary class	Multiplicity	Definition	Constraints
ClinicalTrialRequestForInventoryReport				The Request for Inventory Report communicates a request for provision of an inventory report, which gives current information about inventory levels. The inventory report request is related to finished products as identified GTINs.	
ASSOCIATION	GENERALIZATION	EcomDocument	1..1		
ASSOCIATION	requestForInventoryReportIdentification	Ecom_EntityIdentification	1..1	The unique identification of the inventory request	
ASSOCIATION	sender	Ecom_PartyIdentification	0..1	The sender of the request, usually the sponsor or the DME	
ASSOCIATION	receiver	Ecom_PartyIdentification	0..1	The organization in charge of the physical sites where items are located	
ASSOCIATION		InventoryReportRequestInformation	1..*	The set of parameters necessary to identify the items for which the inventory is requested	
ATTRIBUTE	protocolID	string	1..1	The unique identifier of the protocol	{1..20}
ATTRIBUTE	protocolOwner	GLN	1..1	The identification of the sponsor of the protocol	
InventoryReportRequestInformation					
ASSOCIATION	inventoryReportingPartyLocation	Ecom_PartyIdentification	1..1	The GLN of the physical location for which the inventory is requested	
ASSOCIATION	inventoryReportingParty	Ecom_PartyIdentification	0..1	The GLN of the entity reporting the inventory when different from the receiver of the request in the header	



Content	Attribute / Role	Datatype / Secondary class	Multiplicity	Definition	Constraints
ATTRIBUTE	investigationalProductIdentification	gtin	1..1	The GTIN of the investigational product	
ATTRIBUTE	kitIdentification	string	1..1	The identification of the kit (usually serial+GTIN or protocol number)	{1..200}
ATTRIBUTE	kitType	string	1..1	The medication type (ACTIVE, PLACEBO)	{1..200}
ATTRIBUTE	inventoryReportingDateTime	DateTime	0..1	The reference date of the requested inventory	

4.2 Enumerations (message specific)

Not applicable.

4.3 Code Lists

Class	Codelist	GDD Link



Note: Refer to the Global Data Dictionary (GDD) for the code values.

5 Business Message Examples

5.1 Example 1

Party Information

GS1 Global Location Number	Party Type
9520000000004	Sponsor
9520000000011	Sender - DME
9520000000127	Receiver - Organization receiving the request
9520000000028	Kit Location

Message Example 1

Attribute	Value
ClinicalTrialRequestForInventoryReport	
requestForInventoryReportIdentification	
entityIdentification	10
sender	
GLN	9520000000011
receiver	
GLN	9520000000127
protocolID	PROT1
protocolOwner	9520000000004
InventoryReportRequestInformation	
InventoryReportingPartyLocation	
GLN	9520000000028
investigationalProductIdentification	9520000000530
kitIdentification	9520000000280001
kitType	PLACEBO

Attribute	Value
inventoryReportingDateTime	2020-08-22T00:00:00.000


6 Implementation Considerations

6.1 User Guide

All implementation considerations are discussed in [the GS1 Pharmaceutical Clinical Trial Electronic Messaging Standard Implementation Guideline](#).

6.2 Message Specific Considerations

The detail section of the message includes the list of the specific kits for which the inventory status is required



7 Summary of Changes

Any change in the GS1 standards is done based on the Work Request (WR) submitted by the GS1 User Companies or Member Organisations. All Work Requests are documented in the Work Request system available on the GS1 website: <http://wr.gs1.org>. The system is accessible to registered users. New visitors need to register first, to be able to access it. WRs can be searched by the number referenced in tables below, see: Search Work Requests. The number starts with the two last digits of the year when it was submitted, followed by the consecutive number within that year.



Note: WRs submitted earlier than February 2012 should be searched in Old Change Requests.

7.1 BMS Release 3.4.2

Change	Associated CR Number
<ul style="list-style-type: none"> Initial Draft 	

7.2 BMS Release 3.5

No work requests. Indirect changes due to upgrade to new Shared and eCom Common libraries.

7.3 BMS Release 3.5.1

No work requests. Indirect changes due to upgrade to new Shared and eCom Common libraries.

7.4 BMS Release 3.6

No work requests. Indirect changes due to upgrade to new Shared and eCom Common libraries.

7.5 BMS Release 3.7

Change	Associated CR Number
<ul style="list-style-type: none"> Changed the cardinality of sender and receiver from 1..1 to 0..1 	WR-24-000186

8 Appendices

Not Applicable

9 Acknowledgements

9.1.1 Work Group

Function	Name	Company / organisation
WG chair	Olivia Chauvel (Chair)	CH Victor Dupouy
WG chair	Pierre Fernandez-Barbureau (Chair)	SANOFI
WG chair	Hans von Steiger (Chair)	Pfizer
WG member	Jean-Michel Descoutures	International Hospital Federation (IHF)
WG member	Feargal Mc Groarty	St. James's Hospital
WG member	Vincent Puglia	endpoint clinical
WG member	Mike Meakin	DHL
WG member	Sylvain Alberola	SANOFI
WG member	Céline Bordes-Terrier	CREAPHARM
WG member	Giedré Bracaité	F. Hoffmann-La Roche Ltd.
WG member	Doris Cadart	SANOFI
WG member	Pedro Carvalho	Ipsen
WG member	Robert Giguere	AbbVie
WG member	Nicolas Gryspeert	F. Hoffmann-La Roche Ltd.
WG member	Michael Hoefling	Boehringer Ingelheim Pharma GmbH & Co.KG
WG member	Richard Hwang	Pfizer
WG member	Marco Inserra	CSL Behring GmbH
WG member	Jason James	Bristol-Myers Squibb

Function	Name	Company / organisation
WG member	Matthias Kallmeyer	Boehringer Ingelheim Pharma GmbH & Co.KG
WG member	Nicolas Le Rudlier	CREAPHARM
WG member	Yann Montcourt	Ipsen
WG member	Barry Moore	GlaxoSmithKline
WG member	Marianne Perdrijat	DBV TECHNOLOGIES
WG member	Amy Rupp	CSL Behring GmbH
WG member	Amanda Scott	Biogen
WG member	Jodi Smith-Gick	Eli Lilly and Company
WG member	Richard Austin	PAREXEL International GmbH
WG member	Nick Bobrinsky	nCoup, Inc.
WG member	Arpad Boldis	Deloitte
WG member	Robert Celeste	Center for Supply Chain Studies
WG member	Dilip Daswani	Qliktag Software (formally Zeebric LLC)
WG member	Andreas Geissler	PAREXEL International GmbH
WG member	Mark Hanly	Almac Clinical Technologies
WG member	Mike Hutton	Almac Clinical Technologies
WG member	Kelly Knowles	Bracket Global
WG member	Jitendra Kumar	Thermo Fisher Scientific
WG member	Cherish Lallone	McCreadie Group
WG member	Charlotte Meuldermans	Deloitte
WG member	Fabiana Monaco	PAREXEL International GmbH
WG member	Josef Preishuber-Pflügl	CISC Semiconductor GmbH
WG member	Theodora Sarver	Almac Clinical Technologies
WG member	Michael schlesselman	McCreadie Group
WG member	Colette Thorold	PAREXEL International GmbH
WG member	Elizabeth Waldorf	TraceLink
WG member	Stefan Zietze	PAREXEL International GmbH
WG member	Andrea Zobel	PAREXEL International GmbH
WG member	Shreenidhi Bharadwaj	Syndigo
WG member	Tony Zhang	Syndigo
WG member	Richard Perkins	eClinical Forum
WG member	Olivier Mary	COLCA Medical & Scientific
WG member	Preedee Chenhansa	Tenthpin
WG member	Poppy Abeto Kiese	GS1 Austria
WG member	Andrea Arozamena	GS1 Mexico
WG member	Mahdi Barati	GS1 Iran
WG member	Jiraporn Chalermjirarat	GS1 Thailand
WG member	Shawn Chen	GS1 Thailand
WG member	Mignone Cheng	GS1 Hong Kong, China
WG member	Luiz Costa	GS1 Brasil

Function	Name	Company / organisation
WG member	Sandra Couto	GS1 Canada
WG member	Jesper Kervin Franke	GS1 Denmark
WG member	Stefan Gathmann	GS1 Ireland
WG member	Nicole Golestani	GS1 Canada
WG member	Rami Habbal	GS1 UAE
WG member	Michaela Hähn	GS1 Germany
WG member	Christine Horvath-Hanko	GS1 Hungary
WG member	Anna Klapper	GS1 Germany
WG member	Catherine Koetz	GS1 Australia
WG member	Anne-Claire Krid	GS1 France
WG member	Camille Labeaune	GS1 France
WG member	Ildikó Lieber	GS1 Hungary
WG member	Valerie Marchand	GS1 France
WG member	Adrien Molines	GS1 France
WG member	Zubair Nazir	GS1 Canada
WG member	Alice Nguyen	GS1 Vietnam
WG member	James Perng	GS1 Chinese Taipei
WG member	James Perng	GS1 Chinese Taipei
WG member	Paul Reid	GS1 UK
WG member	Sylvia Reingardt	GS1 Germany
WG member	Sue Schmid	GS1 Australia
WG member	Julian Sin	GS1 Hong Kong, China
WG member	Mig Smith	GS1 UK
WG member	Peter Sturtevant	GS1 US
WG member	Flora Sue	GS1 China
WG member	Sarah Torrance	GS1 UK
WG member	Koichi Uemura	GS1 Japan
WG member	Amber Walls	GS1 US
WG member	Connie Wong	GS1 Canada
WG member	Pete Alvarez	GS1 Global Office
WG member	Jean-Luc Champion	GS1 Global Office
WG member	Steven Keddie	GS1 Global Office
WG member	Neil Piper	GS1 Global Office
WG member	Greg Rowe	GS1 Global Office
WG member	Tania Snioch	GS1 Global Office

9.1.2 Development Team Members

Function	Name	Organisation
GSMP Process Lead	David Buckley	GS1 Global Office



Function	Name	Organisation
Technical Development Lead	Miklós Bolyky	GS1 Global Office
Peer Review	Mark Van Eeghem	GS1 Global Office